Seeking Alpha

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today ...
Nasdaq

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...
Seeking Alpha

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous ...
Monthly Prescribing Reference

Apellis: Certain Injection Kits for Syfovre Should Not Be Used

Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...
Healio

Apellis recommends Syfovre injection kits with 18-gauge filter needles

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Apellis is exclusively distributing injection kits with ...
WCBD

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

A Media Snippet accompanying this announcement is available by clicking on this link. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced ...